Recent clinical successes in liposomal nanomedicines

Wenjie Gu, Gavin P. Andrews, Yiwei Tian*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Downloads (Pure)

Abstract

The intrinsic limitations of cancer therapies promoted the development of safer liposomal nanocarriers capable of better distributing the payload away from normal tissues. Since then, liposomal nanocarriers have been considered the primary drug delivery system for many active pharmaceutical ingredients. These systems are now frequently investigated for the treatment of many infectious diseases. Along with the tremendous progress in the anticancer and antifungal liposomal nanomedicines, we have also gradually realised the difficulties associated with the existing liposomal nanocarrier designs. A better understanding of the nanocarrier-bio interactions may provide a new paradigm in liposomal nanocarrier design and better clinical endpoint efficacy. This short review focuses on the progress and benefits of two market-approved liposomal nanomedicines for cancer and fungal treatments.

Original languageEnglish
Pages (from-to)52-59
JournalInternational Journal of Drug Discovery and Pharmacology
Volume2
Issue number1
DOIs
Publication statusPublished - 03 Feb 2023

Fingerprint

Dive into the research topics of 'Recent clinical successes in liposomal nanomedicines'. Together they form a unique fingerprint.

Cite this